ViroMed Builds New Team to Lead Global Business
Dec 20, 2019 – Seoul, Korea – ViroMed Co., Ltd. (084990: KS) has newly established its Global Business Strategy team in order to accelerate efforts for flagship product VM202’s global market launch. Jehee Suh, previously a partner at McKinsey & Company, has come on board as Director and head of the team.
Mr. Suh joined McKinsey Korea in 2002 after graduating from Seoul National University with a BS in biology. He also worked as a brand manager at Novartis for three years. After completing his MBA at the University of Pennsylvania Wharton School, he returned to McKinsey working out of the Seoul and New Jersey office and gained extensive expertise in business consulting for global companies from various industries including biotech. He first worked with ViroMed earlier this year as the team leader of a McKinsey project advising the company’s global business.
ViroMed continues to expand its activities in global business, especially in the US and is actively involved in CMO/CRO management, project management, FDA review and response, and partnering negotiations across diverse areas including clinical development, regulatory affairs, GMP production, and market research. Sunyoung Kim, DPhil, CEO of ViroMed, commented, "I am confident that our new director will successfully lead the company’s global activities based on his expertise and excellent communication skills. He is expected to play an important role in all major projects to be conducted from next year."
While ViroMed aims to become a top global biotech company with the largest revenue from gene therapy by 2025, and is recruiting from both Korea and the US to achieve this goal, Mr. Suh is also taking the lead in efforts to attract global talent.